Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000171415
Ethics application status
Approved
Date submitted
20/11/2024
Date registered
13/02/2025
Date last updated
13/02/2025
Date data sharing statement initially provided
13/02/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
The NIKI-PT Study - A study of plasma pharmacokinetics of nebulized ketamine in post-operative and trauma patients.
Query!
Scientific title
A study of plasma pharmacokinetics of nebulized ketamine in post-operative and trauma patients in intensive care unit: A phase 2, single site, prospective, interventional, open-label pharmakinetic study,
Query!
Secondary ID [1]
313376
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NIKI-PT Study
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Intensive Care Trauma
335770
0
Query!
Post-operative intensive care
335769
0
Query!
Condition category
Condition code
Anaesthesiology
332593
332593
0
0
Query!
Pain management
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is a single site study with the overall objective to evaluate the pharmacokinetics (PK) of nebulized ketamine in post-operative or trauma intensive care unit (ICU) patients. The study also aims to define the optimal dosing regimens to inform future clinical trails.
Design and setting:
A minimum 20 post-operative or trauma patients in the intensive care unit that meet the inclusion criteria and none of the exclusion criteria will be recruited . In addition to standard analgesia and sedation prescribed by the treating clinician, each patient will receive nebulized ketamine 0.75mg/kg ideal body weight (IBW).
Consent
Eligible patients will be approached by the Principal Investigator. In consultation with the treating team patients will be assessed for competence prior to approaching for consent.
Intervention
All patients continue to received conventional standard of care analgesia (oral, intravenous or epidural) as prescribed by the treating team.
A vibrating mesh nebuliser with mouthpiece and exhalation filter will be used to administer the ketamine. The exhalation filter on the nebulizer expiratory port will eliminate the risk of environmental contamination for those present. Patients will be shown the nebulizer and given detailed instruction and demonstration regarding the use.
For patients on low flow (FiO2 < 0.4) or no oxygen the bacterial filter applied to the exhalation port will reduce fugitive emissions.
For patients on high flow nasal cannula (FiO2 < 0.4) the vibrating mesh nebuliser will be inserted in the circuit on the dry side of the humidifier as per current practice. The patient will be requested to wear a surgical mask to cover their mouth and prevent fugitive emissions.
Ketamine 0.75mg/kg (based on IBW) rounded to the nearest 5kg will be instilled in the nebulizer chamber to make up to 3mL of volume. Nebulization will continue until there is no visible mist.
Biological samples
8 blood samples (3mL each) will be collected into heparinised tubes over two hours (T=0, T+5, +10, +15, +30, +60, +90, +120 minutes) via an existing arterial or central line.
A urine creatinine will be performed from time dosing commences until the end of the two hour sampling period. A 1 mL aliquot of urine from the total sample will be retained to determine renal excretion of the study drug.
Monitoring Fidelity;
A monitoring plan has been established for the study, including a Safety Management Committee (SMC). Protocol adherence will be easily monitored as this is a single site study and the study team will be directly involved in each case. The study will be conducted in accordance with ethical principles consistent with the Declaration of Helsinki, and all relevant national and local guidelines on the ethical conduct of research. The research team will include experienced research coordinators, intensive care specialists, all with Good Clinical Practice (GCP) certification who will have oversight of all study activities and protocol adherence.
All data will be directly entered from the source into the REDCap electronic database. The database has the capacity to run validity checks and logic queries to minimise errors. The study monitor will perform 100% source data verification (SDV) for the first patient recruited and 100% SDV on all patients for informed consent in accordance with the HREC approval, reportable adverse events as per protocol, clinical outcomes and protocol deviations.
Query!
Intervention code [1]
329977
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
339912
0
Renal excretion of the study drug.
Query!
Assessment method [1]
339912
0
Renal clearance of the study drug will be analysed by the Queensland Pathology laboratory as per standard clinical practice.
Query!
Timepoint [1]
339912
0
A 1 mL urine sample will be collected at the end of the sampling period from the total urine volume collected during the two hour creatinine clearance collection.
Query!
Primary outcome [2]
339910
0
To evaluate the plasma pharmacokinetics of single dose nebulized ketamine in post-operative and trauma patients in the ICU.
Query!
Assessment method [2]
339910
0
The following Pk parameters will be examined- area under the concentration–time curve extrapolated to infinity (AUC(0–8)), peak plasma concentration (Cmax,), the time to reach Cmax (Tmax), and the mean residence time (MRT (0–t)), the terminal half-life (T1/2) and the clearance rate (CL) will be obtained. The plasma samples will be analysed for drug concentration using a validated high-performance liquid chromatography (HPLC) method on a Nexera2 UHPLC system coupled to a 8050 triple quadruple mass spectrometer (Shimadzu Corporation, Kyoto, Japan). Bioanalysis will be conducted in accordance with U.S.A FDA guidance for industry on bioanalysis at the Central Bioanalysis Laboratory at the University of Queensland.
Query!
Timepoint [2]
339910
0
Plasma samples will be collected over a two hour sampling window where T=0 is the commencement of nebulization of the study drug. A total of 8 samples will be collected. T0, T+5, +10, +15, +30, +60, +90, +120 minutes
Query!
Primary outcome [3]
339911
0
Urine Creatinine Clearance
Query!
Assessment method [3]
339911
0
Urine Creatinine clearance will be analysed by the Queensland Pathology laboratory as per standard clinical practice.
Query!
Timepoint [3]
339911
0
A two hour urine creatinine clearance will be collected on day of sampling where commencement of sample is the time of start of nebulization.
Query!
Secondary outcome [1]
443871
0
Feasibility of a large randomized controlled trial to provide effective analgesia as an adjunct for conventional therapy for pain management in the patient populations.
Query!
Assessment method [1]
443871
0
Composite secondary outcome Pain will be evaluated using the 1. The validated Numeric Pain Rating Scale (NPRS) which has a scoring domain of 0 (no pain) to 10 (highest conceivable pain) 2. Requirement for break-through analgesia (oral or intravenous or epidural) during the two hour sampling period. 3. Richmond Agitation Severity Score (RASS)
Query!
Timepoint [1]
443871
0
Pain monitoring 1. NPRS and RASS assessment at T=0 (baseline pre-dosing), 30 min, 60 min, end of study (2 hour post nebulization) 2. Break through analgesia during the two hour sampling period post-nebulization
Query!
Secondary outcome [2]
441893
0
Safety
Query!
Assessment method [2]
441893
0
1. vital signs of heart rate, blood pressure and oxygen saturation will be continuously monitored via a Philips Monitor as per standard ICU management.. 2. Glasgow Coma Score (GCS) is measured using an internationally validated clinical tool that measures a person's level of consciousness. 3. monitoring for adverse events of special interest will be done by the trained, qualified research team who perform the study related procedures and the treating medical and nursing team *bronchospasm defined as sudden constriction of muscles in the walls of the bronchioles and as assessed by a clinician or member of the study team *hypoxia defined as SpO2 less than 90% * hypotension defined as SBP less than 90 mmHg, * GCS drop of 2 or more points compared to pre-nebulization score. SMC will identify any serious safety concerns that emerge during the study by regular monitoring of the study progress.
Query!
Timepoint [2]
441893
0
Monitoring for adverse events will occur during the study sampling period and up to 4 hours after end study drug nebulisation. Vital signs (heart rate, blood pressure, oxygen saturation) and GCS will be measured immediately prior to any study intervention (0min), also at 30min and 60min after cessation of nebulisation and up to 4 hours after the end of study drug nebulisation. Other adverse events reasonably suspected by the principal investigator to be related to study-specific nebulization procedures and blood collection will be continuously monitored from the start of study related interventions until 4 hours after the end of nebulisation. The SMC will meet after the 1st, 10th and final patient at end of study.
Query!
Eligibility
Key inclusion criteria
Post-operative or trauma patient in the intensive care unit will be considered if they meet the following criteria:
* Adult greater than or equal to 18 years
* Has an arterial line or central venous line insitu
* Requiring analgesia as per treating team
* Able to provide consent to participate
* Able to inhale nebulized medications
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* suspected or known hypersensitivity to ketamine
* already receiving intravenous ketamine for analgesia
* severe chronic lung disease
* systolic blood pressure less than 100 mmHg
* high oxygen requirement FiO2 greater than or equal to 0.4
* cardiac dysrhythmia
* receiving renal replacement therapy
* liver failure or Child-Pugh C liver cirrhosis
* pregnant or lactating patients
* history of significant mental health disorder or psychological distress as assessed by the PI that will impact consent and/or or prevent participation in the study
* delirium
* previous enrolment in the NIKI-PT study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
The sample size for the study is a minimum of 20 participants. The sample size is based on data from similar studies and will provide a power of 80% and is expected to obtain robust population PK parameter predictions in this patient population, which demonstrates high PK variability.
Continuous variables will be assessed for normality and expressed as means ± SD or medians ± IQR and categorical variables will be expressed as proportions.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
16/02/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
15/08/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
16/08/2026
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
27342
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment postcode(s) [1]
43433
0
4029 - Herston
Query!
Funding & Sponsors
Funding source category [1]
317819
0
University
Query!
Name [1]
317819
0
University of Queensland Research Fellowship
Query!
Address [1]
317819
0
Query!
Country [1]
317819
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Queensland
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
320187
0
None
Query!
Name [1]
320187
0
Query!
Address [1]
320187
0
Query!
Country [1]
320187
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
316503
0
Metro North Health Human Research Ethics Committee B
Query!
Ethics committee address [1]
316503
0
https://metronorth.health.qld.gov.au/research/ethics-and-governance/human-research-ethics-committee
Query!
Ethics committee country [1]
316503
0
Australia
Query!
Date submitted for ethics approval [1]
316503
0
31/01/2024
Query!
Approval date [1]
316503
0
20/06/2024
Query!
Ethics approval number [1]
316503
0
HREC/2024/MNHB/105704
Query!
Summary
Brief summary
Study Title: The NIKI-PT Study - A study of plasma pharmacokinetics of nebulized ketamine in post-operative and trauma patients in intensive care unit: A phase 2, single site, prospective, interventional, open-label pharmacokinetic study. A minimum of 20 patients will be consented and enrolled to receive a single dose of nebulized ketamine 0.75mg/kg (ideal body weight). Over a 2 hour sampling period 8 blood and 2 urine samples will be collected. Assessments will be conducted to report on feasibility, pain, tolerance, concomitant sedatives and analgesia as well as monitoring for study specific adverse events. The hypothesis of the study are that 1. Plasma blood levels of nebulized ketamine in ICU post-operative or trauma patients is adequate to provide analgesia 2. Nebulized ketamine is not associated with any serious adverse events in ICU post-operative or trauma patients
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
138098
0
A/Prof Jayesh Dhanani
Query!
Address
138098
0
ICU Admin Level 3 Ned Hanlon Building Royal Brisbane & Women's Hospital, Butterfield Street, HERSTON QLD 4029
Query!
Country
138098
0
Australia
Query!
Phone
138098
0
+61 7 3646 8897
Query!
Fax
138098
0
Query!
Email
138098
0
[email protected]
Query!
Contact person for public queries
Name
138099
0
A/Prof Jayesh Dhanani
Query!
Address
138099
0
ICU Admin Level 3 Ned Hanlon Building Royal Brisbane & Women's Hospital, Butterfield Street, HERSTON QLD 4029
Query!
Country
138099
0
Australia
Query!
Phone
138099
0
+61 7 3646 8894
Query!
Fax
138099
0
Query!
Email
138099
0
[email protected]
Query!
Contact person for scientific queries
Name
138100
0
A/Prof Jayesh Dhanani
Query!
Address
138100
0
ICU Admin Level 3 Ned Hanlon Building Royal Brisbane & Women's Hospital, Butterfield Street, HERSTON QLD 4029
Query!
Country
138100
0
Australia
Query!
Phone
138100
0
+61 7 3646 8894
Query!
Fax
138100
0
Query!
Email
138100
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF